Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Conway

Showing results (81-90 of 146) with videos related to

Pageof 15
Sort By:
International Journal for Equity in Health|December 3, 2025
Addressing digital exclusion to improve access to HIV and viral hepatitis care for people who experience criminalization: a mixed methods evaluation of a quality improvement projectAmrit Tiwana, Nicola Gale, Mike Mahay, et al.
AIDS Care|April 13, 2022
Disclosure of HIV-serodiscordant relationships and association with viral suppression: results from the Positive Plus One studyJoshua B Mendelsohn, Liviana Calzavara, Sandra Bullock, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 26, 2022
Brief Report: Effect of Antiretroviral Switch From Tenofovir Disoproxil fumarate to Tenofovir Alafenamide on Alanine Aminotransferase, Lipid Profiles, and Renal Function in HIV/HBV-Coinfected Individuals in a Nationwide Canadian StudyArif Sarowar, Carla S Coffin, Scott Fung, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 29, 2013
A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week resultsRichard Elion, Jean-Michel Molina, José Ramón Arribas López, et al.
Topics in HIV Medicine : a Publication of the International AIDS Society, USA|January 16, 2004
Drug resistance mutations in HIV-1Victoria A Johnson, Françoise Brun-Vézinet, Bonaventura Clotet, et al.
Topics in HIV Medicine : a Publication of the International AIDS Society, USA|November 2, 2004
Update of the drug resistance mutations in HIV-1: 2004Victoria A Johnson, Francoise Brun-Vézinet, Bonaventura Clotet, et al.
The International Journal on Drug Policy|February 9, 2019
Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapyJason Grebely, Gregory J Dore, Negar N Alami, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 7, 2021
Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian RegistryFernanda Q Onofrio, Curtis Cooper, Sergio M Borgia, et al.
Plos One|November 25, 2015
A Randomized Trial of Time-Limited Antiretroviral Therapy in Acute/Early HIV InfectionJoseph B Margolick, Linda Apuzzo, Joel Singer, et al.
Topics in HIV Medicine : a Publication of the International AIDS Society, USA|July 3, 2003
Drug resistance mutations in HIV-1Richard T D'Aquila, Jonathan M Schapiro, Françoise Brun-Vézinet, et al.
Pageof 15

Showing results (81-90 of 146) with videos related to

Sort By:
Pageof 15
International Journal for Equity in Health|December 3, 2025
Addressing digital exclusion to improve access to HIV and viral hepatitis care for people who experience criminalization: a mixed methods evaluation of a quality improvement projectAmrit Tiwana, Nicola Gale, Mike Mahay, et al.
AIDS Care|April 13, 2022
Disclosure of HIV-serodiscordant relationships and association with viral suppression: results from the Positive Plus One studyJoshua B Mendelsohn, Liviana Calzavara, Sandra Bullock, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 26, 2022
Brief Report: Effect of Antiretroviral Switch From Tenofovir Disoproxil fumarate to Tenofovir Alafenamide on Alanine Aminotransferase, Lipid Profiles, and Renal Function in HIV/HBV-Coinfected Individuals in a Nationwide Canadian StudyArif Sarowar, Carla S Coffin, Scott Fung, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 29, 2013
A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week resultsRichard Elion, Jean-Michel Molina, José Ramón Arribas López, et al.
Topics in HIV Medicine : a Publication of the International AIDS Society, USA|January 16, 2004
Drug resistance mutations in HIV-1Victoria A Johnson, Françoise Brun-Vézinet, Bonaventura Clotet, et al.
Topics in HIV Medicine : a Publication of the International AIDS Society, USA|November 2, 2004
Update of the drug resistance mutations in HIV-1: 2004Victoria A Johnson, Francoise Brun-Vézinet, Bonaventura Clotet, et al.
The International Journal on Drug Policy|February 9, 2019
Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapyJason Grebely, Gregory J Dore, Negar N Alami, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 7, 2021
Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian RegistryFernanda Q Onofrio, Curtis Cooper, Sergio M Borgia, et al.
Plos One|November 25, 2015
A Randomized Trial of Time-Limited Antiretroviral Therapy in Acute/Early HIV InfectionJoseph B Margolick, Linda Apuzzo, Joel Singer, et al.
Topics in HIV Medicine : a Publication of the International AIDS Society, USA|July 3, 2003
Drug resistance mutations in HIV-1Richard T D'Aquila, Jonathan M Schapiro, Françoise Brun-Vézinet, et al.
Pageof 15